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The Trypanosomatidae family includes the genera Trypanosoma and Leishmania, proto-
zoan parasites displaying complex digenetic life cycles requiring a vertebrate host and an 
insect vector. Trypanosoma brucei gambiense, Trypanosoma cruzi, and Leishmania spp. 
are important human pathogens causing human African trypanosomiasis (HAT or sleep-
ing sickness), Chagas’ disease, and various clinical forms of Leishmaniasis, respectively. 
They are transmitted to humans by tsetse flies, triatomine bugs, or sandflies, and affect 
millions of people worldwide. In humans, extracellular African trypanosomes (T. brucei) 
evade the hosts’ immune defenses, allowing their transmission to the next host, via the 
tsetse vector. By contrast, T. cruzi and Leishmania sp. have developed a complex intra-
cellular lifestyle, also preventing several mechanisms to circumvent the host’s immune 
response. This review seeks to set out the immune evasion strategies developed by the 
different trypanosomatids resulting from parasite–host interactions and will focus on: 
clinical and epidemiological importance of diseases; life cycles: parasites–hosts–vec-
tors; innate immunity: key steps for trypanosomatids in invading hosts; deregulation 
of antigen-presenting cells; disruption of efficient specific immunity; and the immune 
responses used for parasite proliferation.
Keywords: Trypanosomatidae family, parasite–host interactions, immunosuppression, Leishmania sp., 
Trypanosoma brucei sp., Trypanosoma cruzi
CLiNiCAL AND ePiDeMiOLOGiCAL iMPORTANCe 
OF NeGLeCTeD DiSeASeS
Trypanosomatid parasites interact with a wide range of insects and mammals to complete their life 
cycles. Some species, particularly Trypanosoma brucei gambiense, Trypanosoma brucei rhodesiense, 
Trypanosoma cruzi, and Leishmania spp. are pathogenic for humans, causing, respectively, human 
African trypanosomiasis (HAT or sleeping sickness), Chagas’ disease, and cutaneous, mucocuta-
neaous, and visceral Leishmaniasis (VL). These infectious eukaryotic parasites have been described 
and identified over a century ago; however, as of today, no vaccines are available and the availability of 
effective prophylactic and therapeutic drugs remains limited. It is estimated that more than 20  million 
people are infected and that 100,000 people die each year of trypanosomiasis or Chagas’ disease (1). 
Annually, cutaneous leishmaniasis affects around 1 million people, whereas VL is responsible for 
around 500,000 cases annually resulting in over 50,000 deaths (2).
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Tsetse flies (Glossina spp.) transmit HAT-causing 
 trypanosomes. Regarding mortality, it ranks 9th out of 25 
human infectious and parasitic diseases in Africa (3) and is 
estimated to cause the loss of 1.5 million disability-adjusted life 
years per year (4). It is responsible for major setbacks in social, 
agricultural, and economic development in Africa (5) and 
constitutes a severe burden for poor rural populations to whom 
healthcare access is extremely difficult (6) [reviewed in Geiger 
et al. (7)]. The real number of infected people is most probably 
underestimated as it results from a mathematical extrapolation 
of data recorded from only partial epidemiological surveys (5, 
8). In addition, wars, social conflicts and struggles, the presence 
of trypanosome-infected domestic animals, and climate change 
are recognized as factors favoring HAT development and spread 
(9–11). Thus, although the number estimated cases is fewer than 
10,000, this disabling and fatal disease is classified among the 
group of poverty-promoting infectious diseases.
Two distinct forms of HAT exist which are (a) caused by 
two distinct trypanosome subspecies, (b) transmitted by two 
distinct tsetse fly vector species, and (c) widespread in two 
distinct geographic areas. The chronic form, caused by T. brucei 
gambiense, is transmitted by Glossina palpalis sp., and distributed 
in western and central Africa, while the acute form, caused by 
T. brucei rhodesiense is transmitted by Glossina morsitans sp., and 
restricted to East Africa. Despite these differences, the infection 
caused by either the chronic or the acute forms of the disease 
evolve similarly in two distinct clinical phases. During the first 
phase (stage 1 or hemato-lymphatic stage), the trypanosomes are 
present and multiply in the blood and in the lymph nodes; dur-
ing this phase the patients exhibit intermittent fever, headache, 
and joint pain. Stage 2 (meningo-encephalitic stage) begins once 
trypanosomes have invaded the central nervous system (CNS); it 
is characterized by severe neurological disorders (12) [reviewed 
in Ref. (13)]. The two HAT forms differ in the rapidity of their 
respective transition from stage 1 to stage 2: several months or 
even several years for the chronic form, a few months or even 
a few weeks for the acute form. In addition, the severity of the 
latter is much higher than that of the former. The disease is 
generally fatal when not treated. Today, despite the emergence 
of some new drug candidates (14, 15) or drug combinations (16), 
the available chemotherapy remains limited and often generates 
severe side effects or even the development of resistant trypano-
some strains (5, 17). Also, inefficient T. b. gambiense case detec-
tion, chronic infections that are never treated and a long stage 
1 period are important contributors for stable human to human 
transmission in endemic areas. In contrast, for T. b. rhodesiense 
transmission, animals are the main reservoir population, greatly 
affecting therapeutic effectiveness and the impact of control 
measures (18).
Trypanosoma cruzi causes American trypanosomiasis, also 
called Chagas’ disease. This parasite is transmitted to humans 
and other mammals by “kissing bugs,” hematophagous insects 
belonging to the genus Triatoma [or Rhodnius, depending on the 
geographical area where the disease occurs (19)]. In addition, 
transfusion of infected blood, transplantation of contaminated 
organs, and congenital transmission are other important modes 
of T. cruzi transmission. Chagas’ disease is widespread in all 
South American countries affecting about 7–12 million people, 
and putting at risk 60–80 million others (20, 21). Three hundred 
thousand new cases are reported to occur each year, and 21,000 
patients die annually (22). Once a host has become infected, the 
parasite is internalized in the cells of the innate immune system, 
and the infection develops progressively. Similarly to HAT, two 
forms of the Chagas’ disease can be distinguished. The acute form 
is marked by (a) the presence of T. cruzi trypomastigotes in the 
blood stream, (b) high fever, and (c) a severe hepatomegaly. By 
contrast, in the case of the chronic form of the disease, there are 
far fewer parasites present in the blood stream, and the other 
symptoms are also less severe. The chronic form can also be 
“silent” that is, in the absence of any symptom, the infection may 
remain undiagnosed. Nevertheless, 10–20 years later, 5–10% of 
these people will develop anatomical and functional abnormali-
ties at their esophagus and their colon, while ~30% will develop 
myocarditis, leading to heart failure or sudden death (23).
Leishmaniasis is estimated to affect 12 million people in 98 
countries, while ~350 million live in disease-risk areas (24), and 
presents an incidence of around 2 million cases per year. Despite 
more than 500,000 new VL cases per year causing the death of 
more than 50,000 patients (24, 25), this disease is classified among 
the neglected tropical diseases. In 2010, WHO estimated the 
disease to cause the loss of around 2.4 million disability-adjusted 
life years per year (24) [reviewed in Geiger et al. (7)].
Leishmania spp. are transmitted by sandflies belonging to the 
genera Phlebotomus and Lutzomyia. They induce several forms 
of disease in humans, ranging from localized cutaneous lesions 
to VL. VL, the most severe form of Leishmaniasis, is caused 
by parasites of the Leishmania donovani complex (Leishmania 
donovani, Leishmania infantum, and Leishmania chagasi) [see the 
review by Gupta et al. (26)]. Once the mammal host is infected, 
the parasite differentiates intracellularly inside MFs and dissemi-
nates from the skin to the spleen, liver, and bone marrow MFs 
(27). Most patients infected with L. donovani and L. infantum 
develop asymptomatic chronic latent infections. However, ~10% 
of infected people develop fever, severe hepatosplenomegaly, 
pancytopenia, cachexia, and a hyper gamma-globulinemia lead-
ing to the death if untreated (28, 29).
In this review, the authors aimed to summarize the mechanisms 
trypanosomatids use to escape their host deleterious immune 
responses. It will focus on the aspects of the parasite–host–vector 
life cycle; on the host innate immunity and the key steps allow-
ing trypanosomatids to invade their hosts; on the deregulation 
of antigen-presenting cells (APCs); on the disruption of specific 
immunity, as well as on the use of immune responses to favor 
parasite proliferation (Figure 1).
LiFe CYCLeS: PARASiTeS–HOSTS–
veCTORS, COMMON AND DiveRGeNT 
POiNTS
The parasites’ life cycle can be divided into two crucial phases 
allowing the survival inside the hosts (vertebrate and inver-
tebrate). Immediately after their transmission by the insect 
vector (Box  1), parasites have to resist innate immunity and 
BOX 1 | Transmission of parasites belonging to the Trypanosomatidae 
family.
Sandfly: Sandflies belong to the insect order Diptera, suborder Nematocera. 
Within this suborder the family Psychodidae includes biting sandflies in diverse 
genera and non-biting owl-midges or moth flies (genus Psychoda). Among the 
existing phlebotomine genera, two have been proven to be vectors of one of 
the main zoonotic pathogens worldwide, the protozoan parasite Leishmania. 
These belong to the genera Phlebotomus in the Old World and Lutzomyia 
in the New World. Out of more than 800 recognized sandfly species, ~464 
species are found in the New World and 375 in the Old. Among these species, 
only 34 are proven vectors and overall 74 species play a substantial role in 
Leishmania transmission.
Tsetse fly: Tsetse flies belong to the insect order Diptera, suborder 
Cyclorrhapha. They compose a family of their own, Glossinidae, which is 
placed within the Hippoboscoidea due to the morphological and reproductive 
similarities of tsetse flies to keds and other hippoboscid flies. Glossinidae 
includes the single genus Glossina with 23 species, 6 of which are further 
divided into 14 subspecies. Glossina species are arranged in three subge-
nera – Austenina, Nemorhina, and Glossina – which correspond roughly to 
groups of species found in different ecological settings.
Triatomine bugs: The members of the Triatominae belong to the insect order 
of the Hemiptera and the Reduvidae subfamily. Reduvidae are also known as 
kissing bugs, assassin bugs, or triatomines. Most of the 130 or more species 
of this subfamily are hematophagous and all triatomine species are potential 
vector of the Chagas disease parasite Trypanosoma cruzi. Nevertheless, only 
those that are well adapted to living with humans are considered important 
vectors (Triatoma infestans and Rhodnius prolixus).
FiGURe 1 | Mechanisms used by trypanosomatids to escape their 
host deleterious immune response.
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develop either intracellularly (Leishmania and T. cruzi) where 
the parasites are no longer flagellated, or extracellularly in the 
blood flow (bloodstream forms of T. brucei). The diagnostic stage 
of the parasites relies on the presence of bloodstream forms of 
T. brucei gambiense, or amastigotes of Leishmania and T. cruzi 
in the vertebrate host (5, 30, 31). Parasite dissemination in their 
mammalian host occurs after lysis of the host cells (Leishmania 
and T. cruzi), then both intracellular amastigotes of Leishmania 
and bloodstream trypomastigotes of T. cruzi and T. brucei sp. 
are spread via blood circulation.
Transmission from the infected host to the arthropod vector 
occurs when sandflies, triatomine bugs, or tsetse flies take a new 
blood meal, ingesting either infected cells (Leishmania) or free-
living parasites (bloodstream trypomastigotes of T. cruzi and T. 
brucei gambiense). After accomplishing their intravectorial dif-
ferentiation, trypanosomatid parasites have the ability to colonize 
various parts of the arthropod vector’s alimentary tract. Some of 
them are restricted to a single compartment of the alimentary 
tract, i.e., Trypanosoma vivax (Figure  2), while others have a 
more complex life cycle, such as Leishmania, which implies pas-
sage through different compartments of the alimentary tract. The 
transmission of Trypanosomatidae parasites by the blood feeding 
arthropod occurs in three ways: regurgitation (Leishmania/sand-
fly), defecation (T. cruzi/triatomine bugs), or injection (African 
Trypanosomes/Tsetse) (Figure 2). The first phase of arthropod 
colonization takes place in the probocis of the arthropod, or in 
the insect’s midgut. Once inside the midgut of the arthropod vec-
tor, parasite movements are initially restricted by the peritrophic 
membrane that surrounds the bloodmeal during the digestive 
process.
Intracellular amastigotes of Leishmania are released from the 
host cell during the cell breakage process and then differentiate 
into procyclic promastigotes. Depending on the subgenus, once 
promastigotes have been released after the destruction of the 
peritrophic membrane, Leishmania attach to the intestinal epi-
thelium and colonize the intestine after the pylorus or adhere to 
the region near the pylorus. Then, the parasites migrate forward 
to the stomodeal valve where they differentiate into metacyclic 
promastigotes ready to be transmitted during a new blood meal.
For Trypanosoma species, the intravectorial cycle is more 
complex. Trypomastigote forms of T. cruzi change into epimas-
tigotes inside the triatomine vector. After this process, parasites 
inside the midgut of the arthropod begin to multiply concomi-
tantly with the destruction of the peritrophic membrane. Then, a 
second colonization phase takes place: T. cruzi reaches the rectum 
and changes into infective metacyclic trypomastigotes that can be 
transmitted to a mammalian host by defecation.
Bloodstream trypomastigotes of T. brucei or Trypanosoma 
congolense, for example, change into procyclic trypomastigotes 
inside the tsetse fly. Briefly, trypanosomes of the brucei group 
(T. b. brucei, T. b. rhodesiense, or T. b. gambiense) are carried to 
the gut, later passing forward to the proboscis, from where they 
enter the hypopharynx and reach the salivary glands, where the 
infective form are produced. For the T. vivax type, trypanosomes 
migrate forward to the food canal of the proboscis where they 
multiply. Later, infective forms reach the hypopharynx; at this 
stage new hosts can be infected when tsetse flies feed.
During pathogen transmission by arthropods, immediately 
after vessel laceration, platelets form a plug locally and produce 
clotting and vasoconstrictory molecules. Because vertebrate 
homeostasis and inflammation is complex, the saliva of 
hematophagous insects adapted accordingly, containing dozens 
of active compounds (32, 33) [reviewed in Ribeiro et al. (34)]. 
The nature of arthropod feeding modes is thought to have 
evolved independently in several insect orders and families, 
FiGURe 2 | Trypanosomatid parasites life cycles.
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with the salivary composition among insects being typical of 
a convergent evolution scenario (35). During the transmission 
of Trypanosomatidae parasites by their arthropod vector, some 
protein and chemical components of arthropod origin are, 
therefore, co-transmitted to the mammalian host. They can 
then interfere and promote the colonization process of trypa-
nosomatid parasites. The composition of the biological material 
that is co-injected (African trypanosomes and Leishmania) or 
deposited on the skin of the host (American trypanosomes) is 
different in its nature. If we consider the way in which Leishmania 
or African trypanosomes are transmitted, the injected cell-free 
biological material, along with infective parasites, contains a 
large amount of salivary gland proteins. In the case of T. cruzi 
transmission by triatomine, additionnal proteins, peptides, 
and chemicals in the feces of the bugs might also be present 
during the transmission of T. cruzi. In this particular case, the 
invasion of the host by infective parasites occurs later, through 
the bite wound or via mucosal membranes after the instinctive 
 scratching behavior.
A brief overview of the protein salivary constitution found in 
the three arthropods is given in Table 1. Among the salivary com-
ponents, only enzymes that belong to the Apyrase/5′Nucleotidase 
family, Protease family, various protease inhibitors, and the 
Antigen 5 family of proteins have been found to date to be 
present in the transcriptome and/or the proteome of all the 
arthropods involved in the transmission of trypanosomatids 
parasites. A second series of protein families has been com-
monly identified in sandflies and tsetse flies or sandflies and 
triatomine bugs; surprisingly none seems to be common to both 
tsetse flies and triatomine bugs. Lastly, many protein families 
are found specifically in the transcriptome and/or proteome of 
tsetse flies, sandflies, or triatomine bugs. For a vast majority, 
they play a role in vasodilatation, like the Maxalidan found in 
sandflies, Triafestin or Dipatelodipin found in triatomine bugs, 
or the PGE2 synthase found in the transcriptome of the tseste fly 
(see Table 1). In addition, proteins with anti-clotting activity are 
supported by different families of proteins in the three vectors of 
trypanosomatid parasites. Interestingly, the saliva of triatomine 
bugs contains a large number of proteins belonging to the 
lipocalin family (e.g., salivary lipocalin-5), which are described 
to be involved in interactions with the host’s immune response 
(36). Interestingly, they are also found in the transcriptome of the 
digestive tract, more precisely in the rectum of triatomine bugs 
(Rhodnius prolixus) (37). In addition, the lipocalin signature is 
also found in the extracellular material of T. cruzi (Sereno and 
Mathieu-Daudet, unpublished results). Altogether, this suggests 
that redundant activity supported by the protein member of the 
lipocalin family is required to interfere with the complex immune 
response that is activated during trypanosomatids infection.
FACiNG iNNATe iMMUNiTY: KeY STePS 
FOR TRYPANOSOMATiD iNvASiON
Many protozoa cause chronic infections, most probably owing 
to the millenar coevolution between parasites and host immune 
system. The ability to escape and/or modulate both innate and 
adaptive immune responses is crucial for their survival (Box 2) 
[in Lopes et al. (49)]. Parasites have to manipulate host cells in 
order to avoid the production of antimicrobial molecules and to 
benefit from growth factor production. Protozoa have evolved 
specific mechanisms to evade these defenses.
TABLe 1 | Salivary proteins of arthropods.
Name Function SF Ts Tr Reference
Apyrase/5′Nucleotidase Hydrolyze ATP into ADP, which is an inducer of platellet agregation X (34)
X (38)
X (39)
Proteases Hydrolysis of peptide bonds (34)
 – Metalloprotease X X (39)
 – Serine protease  X (38)
Protease inhibitor domains Interact with the proteolytic cascade of the host homeostatic and 
inflammatory processes
  (34)
 – Serpstands for serine protease inhibitor X (38)
 – Kazal domain X (40)
 – Thrombinhibitor X (39)
 – Kunitz domain X (39)
Antigen 5-like Unknown X (41)
X X (42)
X X (38)
Endonuclease Endonucleases are enzymes that cleave the phosphodiester bond with a polynucleotide chain X X (34)
Hyaluronidase Hyaluronidase hydrolyzes components of the skmatrix (39)
Adenosine deaminase purine hydrolase Hydrolization of adenosine into inosine and then hypoxanthine plus ribose. Adenosine 
and inosine induce mast cell degranulation and trigger itching reaction
X X (34)
X X (39)
Phospholipase Hydrolysis the platelet agregation factor X X   (39)
33 kDa familly FXa clotting inhibitor X (34)
Nitrophorin X  X
15–17 kDa familly Unknown X X (34)
(38)
Pyrophosphatase/Phosphodiesterase Hydrolyze dinucleotides that are important inflamatory mediators X (34)
Glycosydase Carbohydrate catabolism X (34) 
Antimicrobial peptides X (34)
Odorant binding protein/D7 superfamilly Antagonize inflammation and hemostasis X (34)
Yellow phlebotominae family Dopachrome convertase activity X (34)
41.9 kDa superfamilly Unknown X (34)
Maxadilan Vasodilatator X (34)
27–30 kDa Unknown X (34)
Possibly multigenic Glossina-specific 
salivary secreted protein
Unknown X (39)
GE-rich salivary proteins Unknown X (39)
Glycine-proline rich familly Unknown X (39)
Fat body and salivary 20 kDa family Unknown X (39)
3–6 kDa salivary peptide Unknown X (39)
Ribonucleases Catalyze the degradation of RNA X (39)
Exonucleases Endonucleases are enzymes that cleave the phosphodiester bond at the 5′ or 3′ end of the chain X (39)
ProstaglandE2 Synthase PGE2 synthesis which is a vasodilatator X (39)
Nitric oxyde synthase Synthesis of nitric oxyde: vasodilatator X (39)
Thioester containing protein Has a reactive cysteine that can form a thioester bond to other, Pathogen, molecules X (39)
Fibrinogen domacontaining/ficolproteins Familly of proteins having the Fibrinogen C motif and Ficoli motif X (39)
Inositol phosphatase Hydrolysis of inositol phosphate and phosphoinositidesubstrates involved cellular process 
related to signal transduction, secretion, and cytoskeletal structure
X (43) 
X (38)
Peptidoglycan recognition protein Pathogen recognition and initiation of innate defense mechanism X (39)
Salivary proteMYS2 Unknown X (38)
Lipocalin The term lipocal means « cup of lipid »; they have the capacity to transport small hydrophobic molecules
 – RPAI Inhibitor of platelet agregation X (43)
 – Triplatin Antiplatelet, vasodilatator X (35)
 – Triafestin Anti-clotting, antipain X (44)
 – Pallidipin Antiplatelet X (45)
 – Triabin Anti-clotting X (46)
 – Procalin Unknown X (47)
 – Dipetalodipin Antiplatelet, vasodilatator X (48)
 – Nitrophorin Antihistamine X (32)
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evasion of innate immunity
After entering a susceptible mammalian host, protozoan parasites 
are targeted by pre-existing soluble factors that can potentially 
recognize and destroy invading parasites or target them for kill-
ing by effector cells. Serum components, such as the complement 
system activation, provide the first line of defense. Alternative 
complement activation is stimulated by non-self surfaces, such as 
those of pathogens, wherein the activation of C3 molecules occurs 
through a proteolytic cleavage promoted by C3 convertases, 
producing C3b molecules that bind covalently to the activator 
surface. These molecules subsequently promote the assembly of 
the membrane attack complex (MAC), which is responsible for 
membrane lysis (50). Leishmania procyclic promastigotes or T. 
cruzi epimastigotes are highly susceptible to complement action, 
whereas the infective metacyclic and bloodstream stages are 
resistant (51, 52).
Leishmania can evade lysis by complement by targeting host 
cells through complement activation. Expression of a modified 
surface lipophosphoglycan (LPG) (53) was found to enhance the 
synthesis of surface proteinase gp63 (54) and PSA-2 (55) prevent-
ing insertion or deposition of the lytic C5b-C9 complex, thereby 
enhancing tolerance of complement-mediated lysis (CML). Some 
mutants of Leishmania major (null-mutants for the referred mol-
ecules) were shown to have less virulence in BALB/c mice and 
high susceptibility to complement lysis (56, 57).
Trypanosoma cruzi blood forms can also survive complement 
activation as they express glycoproteins such as gp160, gp58/68, 
and T-DAF. These proteins can bind to C3b and C4b, which allow 
evasion of complement (58–60).
In humans, only T. brucei gambiense and T. b. rhodesiense 
can develop infection, as other trypanosomes are susceptible to 
two serum complexes with a lytic activity against trypanosomes 
(TLF 1 and TLF 2) (61). Despite their differences, both complexes 
contain apolipoprotein L1 (APOL1) (62). APO L1 in TLF1 is 
taken up through endocytosis via the haptoglobin–hemoglobin 
parasite surface receptor. T. b. gambiense and T. b. rhodesiense 
escape APOL1 trypanolysis by expressing distinct resistance 
proteins (63). The T. b. gambiense-specific gene, TgsGP, is 
essential for human serum resistance as deletion of TgsGP in T. 
b. gambiense renders the parasites susceptible to human serum 
and recombinant APOL1. Reintroducing TgsGP into knockout 
parasite lines restores resistance (64). Protozoa must also evade 
other mediators of innate immunity besides to the complement.
evasion of Cellular innate immunity
Remodeling Host Cell Compartments by 
Intracellular Parasites
Trypanosoma cruzi surface proteins, such as gp82 and gp35/50, 
first adhere to host cell surface receptors inducing calcium-
mediated signaling (65, 66). Afterwards, T. cruzi trypomastigotes 
actively invade mammalian cells and their survival is dependent 
on their ability to subvert a calcium-regulated lysosomal exocytic 
pathway (67). They escape to the cytoplasm after a short period 
in the parasitophorous vacuole, which is necessary for the dif-
ferentiation of trypomastigotes into amastigotes, triggered by the 
low vacuole pH (68). T. cruzi growth and development cannot be 
sustained within the parasitophorous vacuole. However, vacuole 
lysis and escape into the cytosol require exposure to this acidic 
environment, which is essential for the activity of Tc-TOX, a 
molecule secreted by the parasite. This molecule is active at acidic 
pH and forms a membrane pore, an activity which is facilitated 
by a trans-sialidase present on the trypomastigotes’ surface (69, 
70). Another lysosome-independent route of host cell invasion 
has been described using the PI3K-dependent pathway (66, 71).
The initial binding and internalization of Leishmania promas-
tigotes by MFs (72) is associated with/implicates the receptor-
mediated classical endocytic pathway. This pathway involves 
a wide diversity of receptors, opsonic or pattern-recognition, 
such as CR3, CR1, Fc receptors, or lectin receptors such as the 
mannose fucose receptor [mannan-binding protein (MBP)] 
and the integrin family (73, 74). LPG, the main promastigote 
glycoconjugate, plays an essential role in promastigote adhesion 
to MFs, rapidly fusing with lysosomes, transiently inhibiting 
phagosome maturation (75) and generating a parasitophorus 
vacuole that maintains an acidic pH and hydrolytic activity. 
This delay provides enough time for promastigotes to differenti-
ate into more hydrolase-resistant amastigotes. The replicating 
amastigotes ultimately survive and reside within phagolysosomes 
by producing glycoconjugates that are secreted or linked to 
surface of cell, such as GIPLS and proteophosphoglycan (PPG). 
These proteins protect parasites from proteolytic damage (76). 
BOX 2 | innate immune responses.
Innate immunity is based on the recognition of pathogen-associated molecu-
lar pattern molecules (PAMPs), which are present in diverse organisms, but 
are absent in the host and function as an exogenous signal that alerts the host 
to the presence of pathogens. During infection, PAMPs are recognized by 
pattern-recognition receptors (PPRs) that initiate signalling cascades, which 
lead to the activation of transcription factors in innate immune cells and have 
an influence on T-lymphocyte differentiation and functions.
The survival and transmission of pathogenic protozoa depends on their 
ability to evade or subvert host’s innate and adaptive immune responses. 
Evasion of innate immunity by parasitic protozoa is a critical step in their 
host interaction. Innate defenses include the epithelial barrier of the skin, the 
alternative complement cascade and other lytic serum components, lysoso-
mal hydrolases, toxic oxygen and nitrogen metabolites of phagocytes, and 
immunoregulatory functions of dendritic cells (DCs). Trypanosomatids have 
evolved specific mechanisms to evade these defenses. The ability to avoid 
attack by soluble antibodies that neutralize the invasion and opsonize parasi-
tes for phagocytosis is of particular importance to extracellular parasites, such 
as African trypanosomes. The major strategy for evading antibody responses 
is the antigenic variation that protects African trypanosomes from immune 
recognition. The adoption of an intracellular life style, as is done by Leishmania 
and Trypanosoma cruzi, is the simplest way of evading humoral response. 
Intracellular protozoa have a remarkable adaptative capacity as they are able 
to resist killing by remodelling the phagosomal compartments where they 
reside and by interfering with the signalling pathway that leads to cellular acti-
vation. In addition, there is abundant evidence that these protozoan infections 
actively regulate adaptative T-cell responses, resulting in suppressed effector 
functions.
A great challenge to research in immunology and parasitology is the 
development of strategies that foster immunity against protozoan parasites 
and prevent their evasion, chronic or recurrent infections, and associated 
pathologies. A better understanding of the evasion mechanisms employed by 
the parasite is necessary. In the near future, a combination of strategies aimed 
at both early killing of parasites and neutralizing suppressive mechanisms 
could be necessary for effective therapies and vaccines.
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A recent study shows that interaction between Leishmania and 
MFs depends on the polarization of the MF and on the CLR 
protein family (77).
African trypanosomes, by opposition to other protozoan 
parasites, never enter the cells of the host but live extracellularly 
in its fluids. These parasites are constantly exposed to the host’s 
immune monitoring so they have developed the antigenic vari-
ation mechanism, wherein they change their surface proteins to 
prevent elimination (78). This surface coat is made of a densely 
packed array of GPI-anchored variable surface glycoproteins 
(VSG). GPI anchors are cleaved by parasite phospholipase C 
(PLC) (79), resulting in the release of surface VSGs and induction 
of a pro-inflammatory response in cells playing a major role in 
innate immunity (80, 81). During early infection, the shedding 
of soluble VSG glycoproteins by PLC induces a polarized Th1 cell 
response and IFN-γ production; however, in later stages of infec-
tion, the prolonged release of these proteins inhibits MF intracel-
lular signaling and activation (82). Antigenic variation exhibited 
by African trypanosomes remains their central immune escape 
mechanism developed during infection (83).
Interfering with Macrophage Functions and Host Cell 
Signaling Pathways
Leishmania sp. and T. cruzi are able to resist the antimicrobial 
mechanisms induced in phagocytic and even in non-phagocytic 
host cells.
During the acute phase of infection, T. cruzi replicates exten-
sively and releases immunomodulatory molecules (GPI-mucins, 
trans-sialidase, glycoinositolphospholipids GPILS, the cysteine 
proteinase cruzipain), which play a major role in subverting the 
host’s innate immunity. GPI-mucins are responsible for parasite 
surface variability, leading to differential tissue adherence and 
evasion of host innate immune responses. Moreover, they render 
DCs dysfunctional for protective responses (84). T. cruzi uses 
several other mechanisms to escape immune responses from the 
host. In fact, the pathogens that are unable to synthesize sialic 
acids might adsorb these from the host as a way to engage the 
inhibitory siglecs, sialic acid-binding immunoglobulin-like lec-
tins, surface proteins present in several immune cells that bind 
to sialic acid promoting adhesion and signaling (85). Such sialic 
acid–siglec association plays an important role to subvert host’s 
immunity [review in Khatua et al. (86)]. To escape the immune 
responses of the host, T. cruzi manipulates the CD8+ T-cell sia-
lylation (86). When sialic acids–siglec interact, activated CD8+ 
T cells remain unable to kill targets that bear T. cruzi epitopes (87). 
Interestingly, recent findings propose a siglec-mediated CD33 
suppression pathway of cellular function in Leishmania infection 
also (86). When, sialic acids–siglec interact, activated CD8+ 
T cells remain unable to kill targets which bear T. cruzi epitopes 
(87). Interestingly, recent findings propose a siglec-mediated 
CD33 suppression pathway of cellular function in Leishmania 
infection also (86). The evasion mechanism involving T. cruzi 
GIPLs results in the suppression of CD4+ T-lymphocyte activa-
tion (88). The cysteine proteinase cruzipain produced by T. cruzi 
is able to induce both IL-10 and TGF-β secretion and arginase 
expression in MFs resulting in increased replication (89). These 
evasion mechanisms allow the parasite to delay specific responses 
mediated by effector T-cells. In chronic infection, the parasite 
hijacks the host’s TGF-β pathway and maintains, consequently, 
the same rate of parasite death and replication (90). In fact, the 
vaccine efficacy against T. cruzi is called into question as this 
parasite is able to coexist with the immune response developed 
by CD8+ T cells.
Persistence of Leishmania and infection progression are 
caused by the inability of phagocytes to elicit both effective innate 
and adaptative responses (76). Leishmania alters some biological 
functions (disruption of cholesterol dynamics, alteration of the 
DNA methylation status of many host genes with antimicrobial 
functions, and retention of intracellular iron) to promote parasite 
growth (91). Leishmania-induced MF dysfunctions are related to 
the loss of microbicidal (NO, oxygen intermediates) and immu-
nological activities (IL-1, IL-12, MHC, IRF7, and TLR2) (92, 93). 
These dysfunctions are correlated with the alteration of several 
phagocyte signaling events dependent on Ca2+, protein kinase 
C (PKC), mitogen-activated protein kinase (MAPK) and Janus 
kinase 2 (JAK2) (94). JAK2 phosphotyrosine-based signaling 
cascades are particularly important since tyrosine phosphoryla-
tion has been shown to play a critical role in IFNγ-inducible MF 
function regulation, inhibited by Leishmania infection [e.g., 
nitric oxide (NO), major histocompatibility complex (MHC) II, 
Interleukin-IL-12] [review in Forget (95)]. Moreover, the role of 
tyrosine-specific phosphatase SHP-1 in in vivo and in vitro sur-
vival of the parasite and in MF inhibition (96) was shown by the 
use of tyrosine kinase inhibitors (such as PTP SHP-1) that inhibit 
the phosphorylation mediated by the enzyme (96). However, in 
infected MFs, the inhibition of transcription factor STAT1α is 
not due to SHP-1, but probably to specific proteasomal degrada-
tion of the protein (97, 98). Another important aspect in initial 
establishment of infection is the presence of dead parasites in 
the inoculum with exposed phosphatidylserine, which facilitates 
uptake by phagocytes and induces TGF-beta production and 
TNF-alpha downregulation (99).
Like other trypanosomatids, African trypanosomes divert 
the MF inducible metabolism of l-arginine (100). At the begin-
ning of infection, trypanosomes induce the arginase polyamine 
synthesis pathway, which decreases the production of NO, 
and the production of trypanothione reductase, both of which 
needed for host colonization and parasite growth (101). T. brucei 
releases TbKHC1, a kinesin heavy chain isoform, to stimulate the 
activity of arginase-1 (an IL-4Rα-independent signaling enzyme 
but relying on SIGN-R1-dependent IL-10 secretion) for its own 
growth (102). Furthermore, l-arginine depletion decreases the 
expression of the T-cell antigen receptor ζ chain (CD3ζ), the 
principal signal transduction element in this receptor, impairing 
T-cell functions and proliferation (103). TNF-α release by MFs 
exerts a trypanocidal effect (104) and is limited by the activation 
of trypanosome adenylate cyclase. The induction of cyclic AMP 
release by trypanosomes into MF and the activation of protein 
kinase A lead to TNF-α synthesis inhibition (105).
Lectin Pathway
Trypanosomes use several mechanisms to escape from host 
immunity, such as the evasion of complement through the inhibi-
tion of the classical and lectin pathways, via binding to the C3 
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convertase that is essential for complement lysis in all pathways 
and host genetic deficiencies of the complement lectin pathway 
(CLP) (60). Specifically, in the CLP, the host factors mannose-
binding lectin (MBL) and ficolins are able to recognize and bind 
to parasite surface carbohydrates that lead to activation of the 
complement cascade (106). T. cruzi is able to inactivate this lectin 
pathway by neutralizing the binding of MBL to carbohydrate 
(107). MBL induces the lysis of T. cruzi, and a deficiency in these 
host molecules only moderately compromises the defense of the 
host against T. cruzi (108). The receptor C5aR or Bradikinin B2R 
inhibits the translocation of calreticulin to the surface of T. cruzi 
from the endoplasmic reticulum, and inhibits activation of the 
host CI complement component C1, thereby promoting infection 
by T. cruzi (109, 110). In this way, calreticulin acts as a virulence 
factor (111).
Leishmania Lectin-Complement Pathway
Leishmania promastigotes in the bloodstream are known to 
activate the complement system, reported to effectively elimi-
nate the parasite. A greater resistance to CML is observed for 
infective promastigotes (metacyclic) due to the production of 
a surface metalloprotease GP63 and several kinases (26). These 
parasites have evolved to take advantage of receptor-mediated 
phagocytosis as a way of entering target cells and, simultaneously, 
of manipulating MF activation (112). Upon inoculation of the 
vertebrate host, C3b protein binds to the parasite, who alters it 
to an inactive form, preventing elimination. At the same time, 
the inactive C3b molecule at the surface now functions as an 
opsonin ensuring phagocytosis through complement receptor 
3 (CR3), which will in turn inhibit IL-12 production, favoring 
parasite growth (26). This mechanism is independent of NFκB, 
MAPK, IRF, and ETS (113). Several other receptors have been 
described to be important for cell invasion, such as the MBP, that 
plays a role in Leishmania opsonization by triggering a antibody-
independent complement activation mechanism on the MF 
surface (114). Complement activation by Leishmania brazilensis 
on the surface of MFs allows attachment to/invasion of the host 
cell (MF) by the complement receptor link between the MBL and 
a surface LPGs of Leishmania (115). In Leishmania donovani, 
the mannose-fucose receptor (MFR) and the CR3 MF receptor 
were shown to act independently in the attachment of parasites 
by human MFs (116, 117). In addition, macrophagic CR3 recep-
tors differently inhibit Leishmania promastigote binding during 
their growth phase. Lastly, other receptors may be involved in 
MF infection by Leishmania, including MR, TLRs, and FcgRS. 
The infection of DCs by Leishmania involves several receptor/
ligand interactions on the cell surface, such as antibodies FcR, 
a component from complement/CR and proteoglycans/heparin-
binding proteins (118).
The role of polymorphonuclear neutrophil granulocytes 
(PMN) in Leishmania major survival in the host cells is not fully 
understood (see section Control of immune cell population life 
and death). These cells are able to eliminate intracellular parasite 
quickly, except for Leishmania major promastigotes, which can 
survive inside PMN for a few days (119). Leishmania mexicana 
amastigotes residing in the phagolysosome MF produce a large 
quantity of PPG, which can be secreted into the tissue after the 
rupture of infected cells. This PPG interacts with the complement 
system resulting in a decrease in the hemolytic activity of serum. 
It may also prevent the opsonization of Leishmania amastigote. 
PPG stimulates the C cascade by the MBP pathway. Consequently, 
PPG induces complement activation and, thus, contributes to the 
pathology of Leishmaniasis (120).
DeReGULATiON OF ANTiGeN-
PReSeNTiNG CeLLS: PReveNTiNG 
ADAPTATive iMMUNiTY
The main host cells targeted by all three Trypanosomatidae are 
MFs and DCs, both of which play a capital role in the response 
of the immunitary system as they are specialized APC (Table 2). 
In addition, the normal functions of T cells, B cells, and T-helper 
cells (Th1 and Th2) involved in host immune responses, may also 
be modulated, more or less specifically, by the parasites.
Trypanosoma brucei sp./T. congolense, 
and the Human/Animal African 
Trypanosomiasis
These Trypanosoma species, causing either human or animal 
African Trypanosomiases, induce a global MF and T-cell-
mediated immunosuppression, as well as the development of 
suppressive cell phenotypes, in infected cattle or mice (125–128). 
In the case of MFs, both classically and alternatively activated 
cells may develop such suppressive phenotypes (129). They are 
antagonistically regulated and their development is modulated by 
the cytokine environment. So, while classically activated MF are 
induced by type I cytokines (TNF-α, IL-12, IFN-γ) and inhibited 
by type II cytokines (IL-4, IL-10, IL-13, TGF-β), the reverse is 
true for alternatively activated MF (130).
The MF and DC immune response function includes: (a) pro-
cessing of parasite antigens in the endocytic pathway and (b) 
co-stimulation and presentation to T-helper cells (Th cells) of 
trypanosome immunogenic peptides (121). In early infection by 
T. b. rhodesiense (clone LouTat 1), naive VSG-specific Th cells were 
more activated by DCs than MF, which resulted in Th1-mediated 
protective responses (121). Then, the specific Th cells secrete 
molecules that activate both immune systems, innate and adap-
tive, with the aim to destroy the infecting trypanosomes. Thus, 
MF and DCs modulate the adaptive anti-trypanosomal immunity 
by controlling antigen presentation. According to Dagenais et al. 
(121), trypanosomes may have evolved so as to alter antigen pres-
entation for their own survival as a consequence of the pressure 
exerted by the immune system. Depletion of DCs and splenic MFs 
co-stimulatory molecules downregulation by T.  b. rhodesiense 
contributed to inability of both DCs and MFs to generate an 
efficient T-cell response specific to VSG. The ability to modulate 
MF and DC antigen presentation functions allows the parasite to 
escape killing by immune cells and may contribute to the overall 
immunosuppression occurring during trypanosomiasis (131).
Murine T. brucei infection was reported to affect the 
 co-expression of processed antigens and MHC class II molecules 
on the plasma membranes of MFs with the consequence of a 
reduced ability of these cells to present antigen in T.  brucei-infected 
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animals (132). The permanent contact of the trypanosomes with 
the host immune system may have induced in some T. brucei 
strains the ability to modulate MF antigen presentation process. 
This process involves peptide loading onto MHC class II molecules 
and/or [MHC class II-peptide (pMHC)] complex translocation to 
the cell surface for presentation to antigen-specific Th cells (132). 
It was also found that suppressive MFs inhibit the proliferation 
of lymphocytes responding to mitogens and antigens and, thus, 
reduces the proliferative cytokine IL-2 secretion by T-cells (133). 
Moreover, the levels of IL-2 receptors on the surface of these T cells 
were lowered (134). However, it was also reported similar levels of 
immunosuppression in infected animals that are both susceptible 
and resistant; thus, the real efficiency of this mechanism to ensure 
parasite survival in its host remains questionable (135, 136).
The secretome (total excreted-secreted proteins) of T. b. gambi-
ense was shown to impair the lipopolysaccharide (LPS)-induced 
maturation of murine DCs (131). When DCs are stimulated 
by LPS, MHC class II, CD40, CD80, and CD86 molecules are 
upregulated, and cytokines, such as tumor necrosis factor alpha, 
interleukin-10 (IL-10), and IL-6 are released at high levels. In 
T. b. gambiense secretome-stimulated DCs, upregulation and 
secretion of the previous molecules is significantly reduced. 
Moreover, the inhibition of DC maturation resulted in the loss 
of their allostimulatory capacity, leading to a dramatic decrease 
in Th1/Th2 cytokine production by co-cultured lymphocytes. 
These results provide new insights into a novel efficient immu-
nosuppressive mechanism directly involving the alteration of DC 
function, which might be used by T. b. gambiense to interfere with 
the host immune responses in HAT and promote the infection 
process [review in Garzón et al. (131)].
Trypanosoma cruzi and Chagas’ Disease
A number of reports support the idea that, during the infection pro-
cess, Trypanosoma cruzi is able to elicit severe autoimmune responses 
in the host, which contributes significantly to the development of 
the pathogenic process of the Chagas’ disease. T. cruzi amastigotes 
escape host humoral immune responses by developing inside host 
cells. The parasite surface is covered with mucin glycoproteins that 
prevent T. cruzi from being recognized by the host immune system, 
thus favoring its establishment in its host and disease onset. These 
mucins are receptors of residues of sialic acid, which are detached 
by trans-sialidase from glycoconjugates of the host; this chemical 
modification is of interest as the modified mucins are even more 
efficient than the non-sialised glycoproteins were.
In addition, T. cruzi produces several complement regulatory 
molecules, which allow the parasite to prevent complement 
activation, thus allowing it to evade CML (58, 66, 137).
Moreover, T. cruzi induces the production of both Th1 and Th2 
cytokines in infected individuals, and high expression levels have 
been reported for Th1 cytokines IFN-γ and IL-2, as well as for Th2 
cytokines IL-4 and lL-10 (138). In T. cruzi-infected individuals, 
IL-10 gene expression is actively upregulated as indicated by the 
presence of significantly increased levels of the corresponding 
mRNA. This observation suggests that high levels of IL-10 may 
contribute to parasite persistence, as IL-10 is known to inhibit 
host protective Th1 immune responses (139). Thus, the induction 
TABLe 2 | effects of either Trypanosoma brucei sp., Trypanosoma cruzi or Leishmania sp on host immune responsive cells [for T. brucei: Dagenais et al. 
(121); vincendeau and Bouteille (122); for T. cruzi: Chaussabel et al. (84); Flávia Nardy et al. (123); for Leishmania: Bogdan et al. (124)].
T. brucei T. cruzi Leishmania
Macrophages
 – Faulty Ag processing and inability to present Ag to T cells + +
 – Faulty epitope association with MHC-II + +
 – Decrease in T-cell responses + +
 – Th2 response → NOS inhibition and activation of arginase production + +
 – Production of NO, PG, IFN-γ, and TGF-β + +
TGF-β inhibits IL-4, IL-5, and IL-6 → inhibition of B cells differentiation and proliferation
 – Inhibition of caspase-3 production by DC → inhibition of DC apoptosis +
Dendritic cells
 – Inhibition of MHC-II, CD40, CD80, CD86 expression and inhibition of TFN-α, IL-6, IL-10 production: + + +
Inhibition of DC maturation
No differentiation of naive T-CD4+ lymphocytes into
Th1 (producing: IFN-γ, IL-2, TFN-α)
Th2 (producing: IL-4, IL-5, IL-10)
 – DCs depletion + +
 – Inhibition of caspase-3 production → inhibition of DC apoptosis +
 – Production of IL-4 → activation of Th2 response (Th2 secretes IL-4, IL-13)  
→ activation of alternative pathway of macrophage → Leishmania survival
+ +
TH1/TH2
 – Th2 cellular response activation; production of IL-4, IL-10, IL-13, and TGF-β  
→ inhibition of Th1 responses
+ + +
 – Th2 responses + +
Inhibition of macrophages NOS production
Activation of arginase (l-arginine → l-ornithine biosynthesis)
Biosynthesis of polyamines and trypanothione
Favors parasite development, macrophage infection, and parasite survival
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of IL-10 biosynthesis may be crucial for the parasite’s survival in 
its host. By contrast, elimination of the parasite is largely under 
the control of Th1-specific cytokine production (IL-12, IFN-γ, 
TNF-α) (140). IFN-γ produced by NK cells during T. cruzi infec-
tion will activate phagocytic cells, which in turn will produce 
toxic reactive nitrogen intermediates that, ultimately, will kill 
internalized parasites (141). Despite the fact that the induction of 
cytokines leads to both cell-mediated and humoral response and, 
thus, suggested to be important for the development of effective 
immune responses, the susceptibility or resistance of mice to 
T. cruzi infections seems not to be related to a given cytokine 
response (142). Lastly, the ability of T. cruzi to infect a host, to 
survive and develop, and to cause Chagas’ disease depends on a 
complex balance between Th1 and Th2 cytokine production, as 
they display antagonistic effects, the former being protective for 
the host, the latter for the parasite.
Leishmania sp and Leishmaniasis
Basically, the evasion strategies of Leishmania involve diverse 
mechanisms, including the capacity to survive within MFs, 
especially by inhibiting the oxidative burst occurring in activated 
MFs, and to modulate the T-cell immune response. Fixation of 
the complement C3 protein and the subsequent binding to CR1/
CR3 is essential for the initial intracellular survival of infective-
stage promastigotes (143). Once Leishmania are located intracel-
lularly, after receptor-mediated endocytosis, they downregulate 
the active oxygen-dependent killing mechanisms of activated 
MFs (144) [review in Bogdan et al. (145)]. The total cellular and 
membrane acid phosphatase activity correlates with parasite viru-
lence (146). LPG is another potent inhibitor of oxidative burst. 
It works by inhibiting PKC (147), which is the enzyme involved 
in the production of oxidative metabolites. Leishmania produces 
substances with the ability to scavenge the effect of oxidative 
metabolites. Furthermore, Leishmania amastigotes display high 
activity for enzymes that are known to degrade these toxic MF 
products (148). In addition, antiparasitic processes dependent on 
oxygen, phago-lysosomal processes, physical (low pH, osmotic 
stress), or biological factors (lytic enzymes) contribute to the MF 
antiparasitic activity. Hence, the importance of LPG, which is 
directed against the antiparasite effectors produced by the host 
MF (26, 99, 149, 150).
The activation of type 1 T-helper lymphocytes (Thl) by APCs 
requires surface expression of MHC class II, interaction with 
costimulatory receptor–ligand pairs (B7/CD28, CD40/CD40L, 
MHC class II/CD4), and peptide presentation by MHC class 
II [reviewed in Kaye (151)]. In vitro studies demonstrated the 
implementation of various mechanisms Leishmania uses to 
impede T-helper cell responses. It was first demonstrated that 
L. donovani amastigotes interfere, at the transcriptome level, 
with the MHC class II upregulation by IFN-γ [reviewed in 
Reiner (152)]. In addition, Leishmania was shown to be able 
to downregulate MHC class II expression (153). In contrast 
to other intracellular microorganisms (such as Listeria mono-
cytogenes), L. donovani does not upregulate the production 
of B7-1 costimulatory molecules and the heat-stable antigen 
(HSA) in MFs. The MFs were not susceptible to stimuli, that 
normally upregulate B7-1 or the HSA, as does Listeria infection 
or the administration of LPS, of IFN-y or of a crude mixture 
of mitogen-activated T-cells cytokines (154). Another critical 
aspect for Th-cell activation, in addition to the presence of 
MHC class II and costimulatory molecules, is the availability of 
parasite-derived peptides for loading onto the MHC molecules 
(155) [review in Bogdan et al. (145)].
Although Leishmania parasites interact with multiple cell 
types, MFs and DCs are clearly the most important cells influ-
encing the infection progression and outcome. Interleukin 12 
(IL-12) is a critical cytokine necessary for CD4+ Th1 develop-
ment and IFN-γ production (156) [review in Dong and Uzonna 
(157)]. Although MFs are able to phagocytize Leishmania effi-
ciently, their ability to produce IL-12 is selectively impaired by 
the parasites (158). In addition, infection of MFs by Leishmania 
also leads to the production of immunoregulatory cytokines, 
such as IL-10 and TGF-β, which are known for their ability 
to inhibit or deactivate MF functions (see Evasion of Innate 
Immunity) (159).
Several reports show that DCs, highly efficient APCs, play a 
central role in orchestrating immune responses in leishmanial 
disease (160). Although MFs are also specialized APCs, the 
main host cell for Leishmania, as well as the most efficient 
parasite-killing effector, infected MFs do not secrete IL-12 (161); 
hence, they are unable to stimulate an antigen-specific CD4+ 
Th1 cell response (162) [review in Dong and Uzonna (157)]. In 
L. major infection, Ritter et al. (163) demonstrated that CD8α 
and langerin-negative DCs are the principal APCs. They express 
dermal markers of DC (MHC IIhigh, CD11c+, CD11b+, CD8α−, 
and CD205low) (163) and overcome the induction of CD4+ T-cell 
response. In addition, Kautz-Neu et al. (164) reported that, in the 
case of low dose infection, DCs may play a role in the cutane-
ous leishmaniasis/L. major pathogenesis via the induction and 
expansion of regulatory T cells (164–166). In this context, the 
production of IL-12 by APCs is of critical importance as it is able 
to polarize naive T cells into Th1 subset, and, subsequently, to 
induce IFN-γ production (161).
Lastly, intracellular signaling activation cascades that lead to 
the production of effector molecules are important for an effective 
control of pathogens in infected host cells. A number of patho-
gens are able to modulate signal transduction pathways to favor 
their survival (167). Since Leishmania are obligate intracellular 
parasites, their survival inside mammalian host cells is critically 
dependent on their ability to successfully disrupt host cell signal-
ing events [review in Dong and Uzonna (157)], which would 
otherwise lead to the generation of killing effector molecules. To 
avoid killing, the parasites must be actively involved in almost 
every aspect/or all aspects of host cell signaling, manipulating/
inhibiting from the production of microbicide molecules to the 
elicitation of protective cytokines.
DiSRUPTiON OF eFFiCieNT SPeCiFiC 
iMMUNiTY
Although mammalian hosts have developed several immu-
nological mechanisms to eliminate both intracellular and 
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extracellular parasites, trypanosomatids parasites have in turn 
developed  strategies to escape the host immune system, which 
enable their survival and replication. The most striking obser-
vation during infections by trypanosomatids is that specific 
immune responses do exist but they are completely inappropriate 
and ineffective, or are even responsible for immunopathological 
processes (168). Trypanosomatids exhibit different cellular dif-
ferentiation stages and different strategies to interact with their 
host, but in addition to the specificity associated within the gen-
era Leishmania or Trypanosoma, these parasites have developed 
common features in order to subvert their hosts’ immune system 
and ensure successful transmission (99, 123, 169) (Figure 3).
Control of immune Cell Population Life 
and Death
Apoptosis, a major representation of programed cell death, is an 
essential physiological process in maintaining cellular homeo-
stasis, particularly in the immune system, where it participates 
in both eliminating autoreactive or failed cells and controlling 
a proliferative response (170). Trypanosomatids have developed 
refined mechanisms for inducing or preventing the apoptotic cell 
death of their hosts’ immune cells. For instance, Leishmania and 
T. cruzi, additionally to their use of apoptosis mimicry to invade 
MFs (171, 172), are able to regulate apoptosis of target cells 
positively or negatively. This is well illustrated for Leishmania 
with neutrophils, whose lifespan can be either extended by 
the parasite to benefit potentially from the protection of a safe 
intracellular niche (173) or reduced after parasite intake, both 
to limit antiparasite response (174) and fuel parasite growth 
(175). Neutrophils are the first phagocytes recruited to the 
inoculation site (176) and take part in the “Trojan horse” MF 
invasion, where infected apoptotic neutrophils shuttle parasites 
silently (i.e., without inflammatory signal) via phagocytosis to 
their primary host cell; Leishmania is able to delay neutrophil 
apoptosis, allowing the release of chemotactic molecules and 
consequent recruitment of DCs and MFs, as well as the produc-
tion of TGF-beta that will contribute for the silent entry into MFs 
(99, 177, 178). The opposite neutrophil modulations are linked 
to different parameters, such as the genetic background of the 
animal model used or the parasite inoculation route (179), but 
also the molecular pathways modified, such as inhibition of pro-
caspase-3 processing (173), or activation of the survival pathway 
involving extracellular kinases (ERK1/2) (180).
Although they all subvert MF activity during infection, target-
ing the core cell type of the mammalian host immune system, 
trypanosomatids behave differently in managing MF cell death 
depending on the genus considered. Leishmania parasites clearly 
prevent MF apoptosis either when directly housed by this cell 
type (181), or when using the above-mentioned “Trojan horse” 
strategy (177, 178). T. cruzi also uses phagocytosis of apoptotic 
cells by infected MFs to promote parasite growth, upon synthesis 
of transforming growth factor β (TGF-β), prostaglandins, and 
polyamines similarly to Leishmania (87). As they are exclusively 
extracellular, African trypanosomes are constantly exposed to 
the hostile host environment and have, in particular, developed 
mechanisms to cope with the microbicidal action of MFs, 
without specially inducing or repressing apoptosis, but through 
fast induction of the alternative arginine pathway leading to 
polyamines production (80, 182).
One very common feature developed by trypanosomatids 
to ensure immune evasion consists in destroying the lymphoid 
lineage by parasite-driven cell death. Apoptosis of T lymphocytes 
during the contraction phase of an immune response occurs 
FiGURe 3 | Schematic view of the common strategic arsenal developed by trypanosomatids to interrupt effective host immunity, from immune 
evasion to immunosuppression.
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through re-stimulation of activated T cells in a process termed 
activation-induced cell death (AICD), or results from the lack 
of survival factors, commonly referred to as activated T-cell 
autonomous death (ACAD) or death by neglect (183). Using the 
murine infection model for T. cruzi, splenic CD4+ and CD8+ 
T-cells were shown to express CD95 (Fas/Fas ligand apoptotic 
pathway) 2–3 weeks post infection. This observation is in accord-
ance with their death by AICD (184). Leishmania parasites use 
the same strategy to eliminate both CD4+ and CD8+ T-cells, as 
observed in active human cutaneous Leishmaniasis (185), with 
more apoptotic spleen and peripheral blood T-lymphocytes in 
infected dogs compared to control animals (186). However, the 
molecular mechanisms are not as well defined: expression of Fas 
and FasL is increased in splenic human lymphocytes in acute 
disease (187), and Bim, a member of the Bcl-2 family, could also 
be involved in the apoptosis of T-cell in mouse models infected 
with different Leishmania species (188), which can otherwise 
be related to downregulation of kinase activities by Ser/Thr 
phosphatase (189). Extracellular African trypanosomes have also 
developed paracrine mediators able to induce not only CD45-
dependent T-cell death (190) but also memory B-cells apoptosis 
(191, 192), which dramatically impairs the ability of infected 
hosts to develop adaptative immunity. In the same way, T. cruzi 
modulates the death of both IgG(+) B cells reactive to the parasite 
through B-cell–B-cell killing (193) and also induces a marked loss 
of immature B cells in the bone marrow through myeloid cells 
secreting a cyclooxygenase pathway product (194), thus limiting 
host defense and disabling B-cell generation to favor its chronic 
establishment.
The above paragraphs show one of the keypoints/key aspects/
key mechanisms, leading to a successful infection by trypano-
somatids: the ability to subtly modulate the life and death of 
immune cells when interacting with the host immune system.
Abolition of efficient Specific immunity
Molecular Camouflage and Altruistic Behavior
The most well-known system for evading the host’s specific 
immune response is probably the antigenic variation developed 
by African trypanosomes. They have a “repertoire” of variable 
antigenic types (VATs), trypanosome variants in a given popu-
lation, and they can change this surface coating by controlling 
variant-specific surface glycoproteins (VSGs) gene expression. 
When infecting the hosts, the immune system targets the 
major VATs; thus, the parasites with non-targeted or new 
VATs evade destruction. This antigenic variation developed 
by the trypanosomes (several species, subspecies, types, and 
strains) explains why they can escape from an effective immune 
response developed by livestock and human populations in 
different geographical areas (195). Indeed, 10 million identical 
VSGs cover the surface of the trypanosome at any given time. 
On the one hand, they are highly antigenic to focus the host 
humoral immune response; on the other hand, they make it 
possible to circumvent the immune destruction of the para-
site by sacrificing the majority population while maintaining 
an untargeted population (78). Actually, specific immunity 
against the trypanosome’s VSGs is effective, but delayed in time, 
which unfortunately allows the parasite to produce its other 
immunomodulatory effect on the host response. Although 
antigenic variation is a hallmark in African trypanosomes, 
other Trypanosomatidae also use this molecular mechanism to 
evade the host response. In Leishmania, for instance, the central 
repetitive domains of the hydrophilic acylated surface proteins 
(HASPs) are highly variant in their amino acid sequences, 
both within and between species, and clearly play a role in 
immune recognition in the host, albeit not yet fully resolved 
(196). In  the same way, antigenic variation in T. cruzi led to 
the question as to whether Trypanosoma cruzi should be called 
the “cruzi” complex, as the parasite’s diversity is substantial 
not only among strains but also because the interaction of the 
different infecting clones in the host will determine the severity 
of the infection (197).
Disability of Antigen Presentation (See Also Section 
III APCs)
Trypanosomatids, through their complex life cycles and differ-
ent parasitic stages, have also developed sophisticated strate-
gies for interfere with antigen presentation, by decreasing the 
expression of MHC molecules, by inhibiting the costimulatory 
molecules CD80 or CD86, or the synthesis of IL-1. Accordingly, 
specific T-cells are less stimulated and become anergic, leading 
to a non-efficient or an inadequate immune response. During 
progressive illness caused by Leishmania, two concomitant 
phenomena have been observed: an inability of APCs to process 
antigens properly, and the generation of a non-functional T-cell 
response to the processed antigens, despite functional signaling 
of human leukocyte antigen HLA/MHC class II molecules to 
T-cell receptors (TCR) (154, 198, 199). Moreover, the inability of 
APCs to process antigens properly has been linked to the inhibi-
tion phagolysosome biogenesis after Leishmania phagocytosis. 
In fact, the Leishmania surface metalloprotease GP63 cleaves a 
subset of soluble receptors, N-ethylmaleimide-sensitive-factor 
attachment protein receptors (SNAREs), consequently inhibit-
ing the MHC class I presentation of Leishmania exogenous 
antigens, resulting in reduced T-cell activation (92). The strategy 
developed by T. cruzi in restricting antigen presentation is a 
little different, with hyperpolarization of the presented antigen 
repertoire (immunodominance), avoiding complete pathogen 
elimination by host effector cells, and thus favoring host para-
sitism (200). A hallmark of African trypanosome infection is 
that APCs functions are substantially altered, but the weight of 
antigen presentation in the balance between immunosuscepti-
bility and immunotolerance appears to be more complex than 
for other trypanosomatids (121). Early studies in mouse models 
supported reduced presentation of non-parasitic exogenous anti-
gens to T cells, presumably due to the altered display of antigenic 
peptide–MHC class II complexes (127, 132, 201). However, it 
remains unclear how the ability to present antigen is modulated 
among the APCs subsets and to what extent it could affect the 
infection outcome. This was illustrated in resistant mice infected 
with T. congolense, which were able to control infection in an 
MHC class II-restricted immune response manner, but only 
when the IL-10 function was not impaired (202), suggesting 
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precarious effectiveness of antigen presentation in response to 
African trypanosomes.
Trypanosomatid-Induced Imbalance of T-Cell 
Populations
In addition to the apoptotic cell death occurring in immune 
cell populations, the loss in number and functionality of T- and 
B-lymphocytes during trypanosomatid-induced diseases is 
a paradigm referred to as “exhaustion” (203, 204). In T. cruzi 
infections, the repertoire of CD8 (+) T-cells is dramatically 
restricted, which is a particular phenomenon known as immuno-
dominance. The latter, despite targeting a different lymphocyte 
population, can be related to the response to a VAT-specific VSG 
during African trypanosome infections (78). Interestingly, mice 
that developed immune responses against subdominant/cryptic 
CD8 T-cell epitopes corresponding to the immunodominant 
antigen were significantly protected against T. cruzi infection 
(205). In the same way, exhaustion of cross-reactive responses 
to subdominant invariant epitopes by antigenic variation of the 
dominant antigens from African trypanosomes could explain 
the inefficiency of the selected lymphocyte populations, but at 
the same time question on the possibility of restoring protective 
cross-reactive immunity (206). In fact, in terms of lymphocyte 
populations, an increase in the CD4+:CD8+ T-cell ratio and 
IgG1 could be associated with self-cure in African trypanosome-
infected natural host, whereas a decrease in the CD4+:CD8+ 
T-cell ratio and IgM could lead to disease development (207). 
Regarding Leishmania infections, susceptibility or resistance 
were associated long ago with a dichotomy in the development 
of immune response dominated by T-helper 2 (Th2) versus 
Th1, respectively. This was based on experimental data from 
mouse models infected with L. major, but it does not seem to 
be generalized to all Leishmania species, as complex early events 
shape the immune response (208), and especially as polarization 
is not observable in the natural host (human) where Th cells 
and CD4+:CD8+ ratio are either associated with the healing 
process or the development of the different clinical forms (209). 
Additionally, using mutant mouse models, it has been possible 
to explain more clearly the non-cure arising in resistant mice, 
which was due to a Treg cell imbalance (T-regulator cells), whose 
primary function is to suppress ongoing Th1 responses as to con-
trol tissue damage, and that functions as a suppressive pathway 
contributing to parasite persistence (210).
USe OF iMMUNe ReSPONSeS 
FOR PARASiTe PROLiFeRATiON
To escape from host immunity, trypanosomatids interfere with 
the physiological function of various molecules of their host, such 
as arginine and calcium.
Arginine and Trypanosomatidae
To survive and multiply in their host, Trypanosomatidae have the 
possibility of exploiting the host metabolic machinery (Figure 4). 
The mechanisms used are diversified. Several strategies have been 
developed by Trypanosomatidae to escape host immunity. They 
have the potential to act upon the defense mechanism of the 
host, either to create a bypass of the host’s defense mechanism, 
such as the arginine and lectin pathway, which is a mechanism 
of complement evasion, or to scavenge elements produced by the 
host, such as calcium.
Arginine is an amino acid with a basic fundamental role in 
the animal kingdom as a precursor of protein synthesis. It  is 
also the substrate for enzymes leading to the production of NO 
or of polyamines (211). Polyamines are known growth factor 
promoters, and NO is a highly potent antimicrobial  molecule. 
Physiologically, arginine is metabolized via two pathways, 
FiGURe 4 | Arginine used by Trypanosomatidae.
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including a catabolic pathway involving its  degradation by 
 arginase to generate urea and ornithine, a precursor of the 
polyamine pathway. These products of metabolic degradation 
are known to promote Trypanosomatidae growth; on the other 
hand, NO exerts a broad spectrum of antimicrobial activity and it 
is highly toxic for Trypanosomatidae. The parasites Trypanosoma 
brucei (212) or Leishmania major (213) interfere with these 
processes at various steps.
They are able to promote the arginine methylation via 
methyltransferases. In Trypanosoma cruzi (214), a transphos-
phorylase (TcAAP3) acts on the phosphorylation level of the host 
arginine, while L. donovani scavenges the arginine synthesized 
by the host through an amino acid permease (LdAAP3) (215). 
In addition to these processes another system is exploited by 
Trypanosomatidae, which consists in using the host arginine for 
itself. Leishmania can hydrolyze the l-arginine of the host by an 
l-arginine aminohydrolase (E.C.3.5.3.1.) allowing the parasite 
to escape the production of host microbicidal NO (216). A few 
species, such as Leishmania amazonensis, Leishmania braziliensis, 
and Leishmania chagasis promastigotes, have a significant effect 
on this NO production using an irreversible inhibitor of nitric 
oxide synthase (iNOS) (217).
Free Calcium in Trypanosoma
The free calcium ion is important for trypanosomatid survival 
and multiplication (Figure  5). These pathogens are able to 
scavenge the ion either from the host cell intracellular stock 
or from the host extracellular stock. In Trypanosoma, intracel-
lular calcium is stocked in a peculiar cell structure called the 
acidocalcisome (218). Cleavage activation of the Trypanosoma 
cruzi trypomastigote factor (PGFT) activates the PLC pathway 
that induces the release of intracellular free calcium via inositol, 
1,4,5-triphosphate (IP3) sensitive intracellular channels. Calcium 
release induced the reorganization of host cell microfilaments, 
which play a crucial role in mammalian host cell invasion by 
Trypanosoma cruzi (219). Calcium is taken up from the sur-
rounding environment of the parasite through the activity of 
a Ca2+-ATPase (220). In Trypanosoma, the intracellular stock 
of free calcium, pyrophosphates, and polyphosphates is stored 
in specialized organites called the acidocalsisome (221). Ca2+ 
entry is regulated by PLA2 and activated by arachidonic acid 
and Ca2+ itself (222). Arachidonic acid appears to play a major 
role in calcium release from the cellular acidocalcisome (223). 
Arachidonic acid and the melittin peptide, of amphiphilic nature, 
induce an increase in intracellular calcium concentration in 
procyclic Trypanosoma brucei, Leishmania donovani promas-
tigotes, and Trypanosoma cruzi amastigotes. In Trypanosoma 
cruzi, calcium plays a role in flagella motility via the flagellar 
calcium-binding protein (FCaBP), in all stages of develop-
ment. This calcium-binding protein is localized in the flagellar 
membrane and acts in a calcium dose-dependent manner for 
its activity. In Trypanosoma brucei and Trypanosoma cruzi, 
calcium is carried by vacuolar transporter chaperone 4 (224). 
In Trypanosoma brucei, calcium release from intracellular storage 
acts through the activation of phosphoinositide phospholipase 
C (PI-PLC), which hydrolyzes phosphatidylinositol (PI) and PI 
4,5-biphosphate (PIP2), involving the inositol 1,4,5-triphosphate 
(IP3)/diacylglycerol (DAG) pathway for this activation (225).
Calcium ion in Leishmania
In Leishmania, calcium is stored in two cellular compartments: 
vesicles in mitochondria (226) and in the acidocalcisome (218) 
(Figure  6). The osmotic regulation of intracellular calcium is 
crucial for parasite survival and involves a set of ATPases whose 
location varies from the plasma membrane to the sarco/endoplas-
mic reticulum (227).
During infection of the MF, a burst occurs in the calcium 
steady-state concentration (228). During this process, free 
 calcium from vesicle storage is released by the action of IP3 
receptors, ryanodine receptor channels (RyRs), two-pore Ca(2+) 
channels (TPCs), and intracellular transient receptor potential 
(Trp) channels, which are mammalian channel homologs (229). 
This disturbance in intracellular calcium concentration has 
several consequences: (i) activation of guanylyl cyclase, which 
FiGURe 5 | Calcium used by Trypanosoma.
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increases parasite infectivity (230); (ii) the release of calcium 
from the acidocalcisome, due to alkalization of the cytoplasmic 
pH (231); (iii) depolarization of the mitochondrial membrane 
potential and induced ATP loss, generating Leishmania cell death 
by apoptosis (232). Calcium channel blockers and nucleotides 
(UTP) possess anti-Leishmania activity (233, 234).
CONCLUSiON
In conclusion, Trypanosomatidae parasites are multistage organ-
isms that require a vertebrate host and an insect vector, in which 
they undergo many cell differentiations. Designing drugs that 
persistently interrupt the life cycles of these parasites requires a 
comprehensive understanding of their biology and the mecha-
nisms involving host–vector–parasite interactions. Owing to the 
difficulties in controlling diseases caused by trypanosomatids, 
many studies have been focused on the strategies developed by 
the different parasites to escape host immune defenses, with a 
view to characterizing weaknesses in their escape processes that 
could be used to fight them. The goal of our review is to focus on 
these strategies developed by the different parasites to escape host 
immune defenses to improve knowledge of these interactions 
in order to initiate novel strategies for controlling the diseases 
caused by Trypanosomatidae parasites.
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